Anticoagulation Nursing Guide 2026

⚕️ Medical Disclaimer: This content is for educational purposes only and is intended for licensed healthcare professionals. It does not constitute medical advice and should not replace clinical judgment, facility protocols, or physician orders. Always verify medications, doses, and procedures with your institution's guidelines.

Part of the ICU Emergencies Hub — browse every related guide in one place.

This article was created with AI assistance.

Heparin drips, warfarin management, DOACs, reversal agents, and bleeding protocols — everything a nurse needs at the bedside.

1. Why Anticoagulation Matters

Anticoagulants prevent clot formation and extension. They do NOT dissolve existing clots (that's thrombolytics). Nurses manage these high-alert medications daily — understanding the drug, the lab, the antidote, and the bleeding signs is non-negotiable.

HIGH-ALERT MEDICATION: Anticoagulants are among the most common causes of preventable adverse drug events. Independent double-checks required per policy.

2. Unfractionated Heparin (UFH)

Mechanism

Binds antithrombin III → inactivates thrombin (IIa) and Factor Xa. Requires antithrombin III — if AT-III depleted (HIT, liver disease), heparin is less effective.

Monitoring: aPTT and Anti-Xa

Lab	Therapeutic Range	Notes
aPTT	60–100 seconds (varies by protocol)	Check 6 hours after rate change; check q6h until stable 2× in a row, then q24h
Anti-Xa (heparin level)	0.3–0.7 units/mL	More accurate in patients with lupus anticoagulant, extreme BMI, or abnormal baseline aPTT
Platelet count	Check baseline + every 2–3 days	Screen for HIT — see below

UFH Drip Protocol (Weight-Based)

aPTT Result	Action
<40 sec	Bolus 80 units/kg IV + increase rate 4 units/kg/hr
40–59 sec	Bolus 40 units/kg IV + increase rate 2 units/kg/hr
60–100 sec (goal)	No change
101–120 sec	Decrease rate 1 unit/kg/hr (no bolus)
121–150 sec	Hold 30 min + decrease rate 2 units/kg/hr
>150 sec	HOLD infusion + call provider + recheck aPTT in 4 hr

Nursing pearl: Standard UFH concentration = 25,000 units in 250 mL NS = 100 units/mL. Always verify concentration before programming pump.

Heparin-Induced Thrombocytopenia (HIT)

HIT Type I: Mild, non-immune, platelets drop 10–30%, resolves on its own. Days 1–2.
HIT Type II: Immune-mediated (antibody against PF4-heparin complex). Paradoxical THROMBOSIS. Days 5–14. Platelets fall >50% or to <100k.

HIT Type II Management:

STOP all heparin immediately (including flushes, coated catheters)
Switch to a direct thrombin inhibitor: argatroban (preferred if hepatic function intact) or bivalirudin
Send HIT antibody (PF4/heparin ELISA) + serotonin release assay (SRA = gold standard)
Do NOT give platelets (can worsen thrombosis)
Warfarin only AFTER platelets recover >150k

Reversal: Protamine Sulfate

Indication	Dose	Notes
UFH reversal	1 mg protamine per 100 units UFH given in last 2–4 hours (max 50 mg)	Give slowly over 10 min — too fast → hypotension, bradycardia, anaphylaxis
LMWH partial reversal	1 mg protamine per 1 mg enoxaparin (if within 8 hr)	Only ~60% reversal of anti-Xa activity

Protamine caution: Patients with fish allergy, previous protamine insulin exposure, or vasectomy (anti-sperm antibodies cross-react) have higher anaphylaxis risk. Have epinephrine at bedside.

3. Low Molecular Weight Heparin (LMWH)

Common Agents

Drug	Trade Name	Typical Dose	Key Facts
Enoxaparin	Lovenox	Treatment: 1 mg/kg SQ q12h or 1.5 mg/kg SQ daily Prophylaxis: 40 mg SQ daily	Renal-dosed: CrCl <30 → reduce to 1 mg/kg q24h for treatment
Dalteparin	Fragmin	VTE treatment: 200 units/kg SQ daily	Preferred in cancer-associated VTE
Fondaparinux	Arixtra	Treatment: 5–10 mg SQ daily (weight-based) Prophylaxis: 2.5 mg SQ daily	Factor Xa inhibitor only; NO protamine reversal; contraindicated if CrCl <30

LMWH monitoring: Routine monitoring NOT required in most patients. Monitor anti-Xa level (4 hr after dose) in: pregnancy, extremes of weight (<50 kg or >150 kg), renal impairment, pediatric patients.

4. Warfarin (Coumadin)

Mechanism

Inhibits vitamin K-dependent clotting factors: II, VII, IX, X (and proteins C and S). Takes 2–3 days for full effect because existing factors must be cleared. BRIDGE therapy with heparin needed for therapeutic transition.

Monitoring: INR (International Normalized Ratio)

Indication	Target INR
DVT/PE treatment, A-Fib stroke prevention	2.0–3.0
Mechanical heart valve (mitral position)	2.5–3.5
Mechanical heart valve (aortic position)	2.0–3.0
Antiphospholipid syndrome with recurrent clots	2.5–3.5

Warfarin Drug Interactions (NCLEX Favorite)

Drugs that INCREASE INR (potentiate warfarin): amiodarone, fluconazole, metronidazole, ciprofloxacin, trimethoprim-sulfamethoxazole, aspirin, NSAIDs, clopidogrel, fish oil

Drugs that DECREASE INR (inhibit warfarin): rifampin, carbamazepine, phenytoin, phenobarbital, cholestyramine

Foods high in Vitamin K (decrease INR): leafy greens (spinach, kale, broccoli) — teach patients to keep vitamin K intake CONSISTENT, not avoid it entirely

Warfarin Reversal

INR + Situation	Treatment
INR 4.5–10, no bleeding	Hold 1–2 doses; consider PO vitamin K 1–2.5 mg
INR >10, no bleeding	Hold warfarin + PO vitamin K 2.5–5 mg; recheck INR in 24 hr
Any INR + serious bleeding	4-Factor PCC (Kcentra) + IV vitamin K 10 mg slow infusion; FFP if PCC unavailable
Life-threatening bleeding (ICH, GI hemorrhage)	4-Factor PCC 25–50 units/kg IV + IV vitamin K 10 mg

Vitamin K IV pearls: Give diluted in 50–100 mL NS, infuse over 30–60 min. Rapid IV vitamin K → anaphylaxis. Effects begin in 6–8 hr; full reversal in 24 hr. Note: IV vitamin K will make re-anticoagulation with warfarin difficult for 1–2 weeks.

Bridging Therapy

When initiating warfarin: start heparin (UFH or LMWH) simultaneously. Continue until INR is therapeutic for 2 consecutive days. Protein C has a shorter half-life than clotting factors — starting warfarin alone can cause a transient hypercoagulable state (warfarin-induced skin necrosis).

5. Direct Oral Anticoagulants (DOACs)

Factor Xa Inhibitors

Drug	Brand	Standard VTE Dose	Monitoring	Key Facts
Rivaroxaban	Xarelto	15 mg BID × 21 days, then 20 mg daily with evening meal	No routine monitoring	Take with food for absorption; once-daily dosing increases adherence
Apixaban	Eliquis	10 mg BID × 7 days, then 5 mg BID	No routine monitoring	Least renal clearance (~25%) → preferred in CKD
Edoxaban	Savaysa	60 mg daily (after 5–10 days parenteral anticoagulation)	No routine monitoring	Reduce to 30 mg if CrCl 15–50, body weight ≤60 kg, or P-gp inhibitors

Direct Thrombin Inhibitor

Drug	Brand	VTE/A-Fib Dose	Key Facts
Dabigatran	Pradaxa	150 mg BID (after 5–10 days parenteral AC)	Do NOT crush or chew capsules; store in original blister; highly renal-cleared — avoid if CrCl <15–30

DOAC Reversal Agents

Agent	Brand	Reverses	Dose	Notes
Idarucizumab	Praxbind	Dabigatran ONLY	5 g IV (2 × 2.5 g vials given within 15 min)	Immediate reversal; humanized antibody fragment
Andexanet alfa	Andexxa	Rivaroxaban & Apixaban (Factor Xa inhibitors)	Low dose (400 mg IV bolus + 480 mg infusion) or High dose (800 mg bolus + 960 mg infusion) based on drug/timing	Approved for life-threatening or uncontrolled bleeding
4-Factor PCC (Kcentra)	Kcentra	All DOACs (off-label if specific reversal agents unavailable)	25–50 units/kg	Contains II, VII, IX, X; faster and more effective than FFP

No DOAC reversal agent on hand? Activate Factor Xa inhibitor reversal protocol: 4-factor PCC 50 units/kg + hold next doses. FFP has no role for DOAC reversal (doesn't bind the drug).

6. Argatroban & Bivalirudin (HIT / Procedures)

Drug	Mechanism	Monitoring	Use	Key Facts
Argatroban	Direct thrombin inhibitor	aPTT 45–100 sec (1.5–3× baseline)	HIT, PCI without HIT	Hepatically metabolized — reduce dose in liver disease; elevates INR (affects warfarin transition)
Bivalirudin	Direct thrombin inhibitor	ACT (activated clotting time) for PCI; aPTT for infusions	PCI, HIT with renal failure, acute ischemic stroke	Renally cleared; short half-life (~25 min); minimal drug interactions

7. Bleeding Risk Assessment & Management

HAS-BLED Score (Bleeding Risk in A-Fib)

H=Hypertension uncontrolled, A=Abnormal renal/liver function (1–2 pts), S=Stroke history, B=Bleeding history/predisposition, L=Labile INR, E=Elderly (>65), D=Drugs (antiplatelets/NSAIDs) or alcohol (1–2 pts). Score ≥3 = high bleeding risk (does NOT necessarily mean stop anticoagulation — weigh against stroke risk).

Bleeding Signs: What to Assess

Head-to-toe anticoagulation assessment:

Neuro: New headache, confusion, weakness (ICH)
Eyes/ears: Visual changes, epistaxis
GI: Hematemesis, melena (black tarry stool), hematochezia (bright red), guaiac test all stools
GU: Hematuria (pink/red/brown urine)
Skin: Bruising, petechiae, purpura, prolonged bleeding from puncture sites
Joints: Hemarthrosis (swelling, pain, warmth)
Vitals: Tachycardia, hypotension, decreasing H&H (retroperitoneal bleed often silent)

Bleeding Response Protocol

STOP anticoagulant (and hold next scheduled dose)
Notify provider immediately — report drug, dose, last dose, current lab values (INR/aPTT/anti-Xa), amount/location of bleeding
Establish/maintain IV access (2 large-bore IVs)
Labs: CBC, CMP, coagulation panel (PT/INR/aPTT/fibrinogen), type and screen/cross
Prepare reversal agent as ordered
Assess for hemodynamic instability → fluid resuscitation, blood products
Document time of bleeding onset, interventions, response

8. Perioperative Anticoagulation Bridging

Drug	Hold Before Surgery	Resume After
Warfarin	5 days; check INR day before → if >1.5, give low-dose vitamin K	12–24 hr if hemostasis achieved
Dabigatran	CrCl >50: 2 days; CrCl <50: 4 days	24 hr minor; 48–72 hr major
Rivaroxaban/Apixaban/Edoxaban	24 hr (minor); 48 hr (major/neuraxial)	24 hr minor; 48–72 hr major
UFH drip	4–6 hr (half-life ~1.5 hr)	Per surgeon
Enoxaparin (prophylaxis)	12 hr	12–24 hr
Enoxaparin (treatment dose)	24 hr	24–48 hr

NCLEX High-Yield Anticoagulation Points

Heparin antidote = protamine sulfate
Warfarin antidote = vitamin K (and 4-factor PCC for urgent)
Dabigatran reversal = idarucizumab (Praxbind)
Rivaroxaban/Apixaban reversal = andexanet alfa (Andexxa)
Heparin monitors: aPTT (goal 60–100 sec); LMWH monitors: anti-Xa (if needed)
Warfarin monitors: INR (goal 2–3 for most indications)
INR ELEVATED too much → holds warfarin and give vitamin K; INR too LOW → increase dose or add bridge
LMWH: NOT fully reversible with protamine (only ~60%)
Warfarin INCREASES INR; everything on the "inhibits warfarin" list DECREASES INR
HIT: STOP all heparin forms; switch to argatroban or bivalirudin; do NOT give platelets
DOACs do NOT require routine INR/aPTT monitoring
Warfarin + leafy greens: consistent intake is key — don't avoid, just keep consistent

Get The ICU Notebook Newsletter

Clinical tools and career insights for ICU nurses. One email per week, no fluff.

Yes, send it free

No spam. Unsubscribe any time.

Anticoagulation Nursing Guide 2026

1. Why Anticoagulation Matters

2. Unfractionated Heparin (UFH)

Mechanism

Monitoring: aPTT and Anti-Xa

UFH Drip Protocol (Weight-Based)

Heparin-Induced Thrombocytopenia (HIT)

Reversal: Protamine Sulfate

3. Low Molecular Weight Heparin (LMWH)

Common Agents

4. Warfarin (Coumadin)

Mechanism

Monitoring: INR (International Normalized Ratio)

Warfarin Drug Interactions (NCLEX Favorite)

Warfarin Reversal

Bridging Therapy

5. Direct Oral Anticoagulants (DOACs)

Factor Xa Inhibitors

Direct Thrombin Inhibitor

DOAC Reversal Agents

6. Argatroban & Bivalirudin (HIT / Procedures)

7. Bleeding Risk Assessment & Management

HAS-BLED Score (Bleeding Risk in A-Fib)

Bleeding Signs: What to Assess

Bleeding Response Protocol

8. Perioperative Anticoagulation Bridging

Related Articles